Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanna Roder

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
International Journal of Medical Informatics|October 3, 2021
Predicting prognosis in COVID-19 patients using machine learning and readily available clinical dataThomas W Campbell, Melissa P Wilson, Heinrich Roder, et al.
Lung Cancer (Amsterdam, Netherlands)|February 4, 2018
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapyFrancesco Grossi, Carlo Genova, Erika Rijavec, et al.
BMC Cancer|March 22, 2018
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patientsMary Jo Fidler, Cristina L Fhied, Joanna Roder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Journal for Immunotherapy of Cancer|March 31, 2019
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutationsPaolo A Ascierto, Mariaelena Capone, Antonio M Grimaldi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone, J Stuart Salmon, Dean Billheimer, et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab|December 11, 2023
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidanceMatthew A Koc, Timothy Aaron Wiles, Daniel C Weinhold, et al.
Cancers|July 2, 2021
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based TestDevalingam Mahalingam, Leonidas Chelis, Imran Nizamuddin, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 21, 2010
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung, Erin H Seeley, Heinrich Roder, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
International Journal of Medical Informatics|October 3, 2021
Predicting prognosis in COVID-19 patients using machine learning and readily available clinical dataThomas W Campbell, Melissa P Wilson, Heinrich Roder, et al.
Lung Cancer (Amsterdam, Netherlands)|February 4, 2018
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapyFrancesco Grossi, Carlo Genova, Erika Rijavec, et al.
BMC Cancer|March 22, 2018
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patientsMary Jo Fidler, Cristina L Fhied, Joanna Roder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2020
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint InhibitorsMirte Muller, Karlijn Hummelink, Daan P Hurkmans, et al.
Journal for Immunotherapy of Cancer|March 31, 2019
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutationsPaolo A Ascierto, Mariaelena Capone, Antonio M Grimaldi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2009
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumabDavid P Carbone, J Stuart Salmon, Dean Billheimer, et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab|December 11, 2023
Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidanceMatthew A Koc, Timothy Aaron Wiles, Daniel C Weinhold, et al.
Cancers|July 2, 2021
Detection of Hepatocellular Carcinoma in a High-Risk Population by a Mass Spectrometry-Based TestDevalingam Mahalingam, Leonidas Chelis, Imran Nizamuddin, et al.
The Oncologist|August 25, 2018
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung CancerConsuelo Buttigliero, Frances A Shepherd, Fabrice Barlesi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 21, 2010
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patientsChristine H Chung, Erin H Seeley, Heinrich Roder, et al.
Pageof 3